All In Biotech

Drug Trial Radar · NCT07417553

A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis

A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Apr 15, 2026

Primary completion

Jul 27, 2026

Study completion Jul 27, 2026

Sponsor

Sponsor type
Industry
Collaborators
The Second Affiliated Hospital of Chongqing Medical University
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial employs a single-arm, open-label, multicenter clinical trial design. All study participants who meet the inclusion/exclusion criteria will receive Hydronidone treatment for 4 weeks. The study includes a screening period (up to 21 days) to assess the eligibility of participants. Eligible participants will enter the treatment period and receive Hydronidone capsules at a dosage of 270 mg TID (30 mg/capsule, 3 capsules each time, three times daily, taken orally half an hour before meals) for 28 consecutive days. Participants will return for a follow-up visit on Day 28 (±3 days) after the first dose for safety assessments. All adverse events (AEs) and concomitant medications occurring during the study period must be recorded. After the treatment period, participants will enter a follow-up period to monitor any delayed adverse events. Participants who complete the final follow-up visit are considered to have completed the study. Throughout the study, participants must maintain the stability of all their pre-existing treatment regimens, including antiviral therapy and medications for other comorbid conditions.

Conditions

  • Chronic Hepatitis B-related Liver Fibrosis

Interventions

  • Hydronidone capsulesDrug

    Hydronidone capsules,30 mg/capsule, 3 capsules each time, three times daily, taken orally half an hour before meals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs).Time frame: Within 28 days
  2. Severity of adverse events (AEs) and serious adverse events (SAEs).Time frame: Within 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing Medical University Second Affiliated Hospital

    Chongqing, Chongqing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.